Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide

Molecular Neurodegeneration

Volumn 4, Issue 1, 2009, Pages

  Yamin, Rina ^a   Zhao, Cheng ^a   O'Connor, Peter B ^a   McKee, Ann C ^a,b   Abraham, Carmela R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL PEPTIDE HYDROLASE; AMINO ACID; AMYLOID BETA PROTEIN; MONOMER; OLIGOMER; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; MASS SPECTROMETRY; MUTATION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE;

MAMMALIA;

EID: 69049097135     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-4-33     Document Type: Article

References (42)

1. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. J Hardy DJ Selkoe, Science 2002 297 353 356 12130773
2. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. MS Forman JQ Trojanowski VM Lee, Nat Med 2004 10 1055 1063 15459709
3. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. CJ Pike AJ Walencewicz CG Glabe CW Cotman, Brain Res 1991 563 311 314 1786545
4. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. A Lorenzo BA Yankner, Proc Natl Acad Sci USA 1994 91 12243 12247 7991613
5. The toxicity in vitro of beta-amyloid protein. LL Iversen RJ Mortishire-Smith SJ Pollack MS Shearman, Biochem J 1995 311 Pt 1 1 16 7575439
6. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. MJ Rowan I Klyubin Q Wang NW Hu R Anwyl, Biochem Soc Trans 2007 35 1219 1223 17956317
7. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. CC Glabe, Subcell Biochem 2005 38 167 177 15709478
8. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. GM Shankar S Li TH Mehta A Garcia-Munoz NE Shepardson I Smith FM Brett MA Farrell MJ Rowan CA Lemere CM Regan DM Walsh BL Sabatini DJ Selkoe, Nat Med 2008 14 837 842 18568035
9. Neuropathological stageing of Alzheimer-related changes. H Braak E Braak, Acta Neuropathol 1991 82 239 259 1759558
10. Correlations of synaptic and pathological markers with cognition of the elderly. DW Dickson HA Crystal C Bevona W Honer I Vincent P Davies, Neurobiol Aging 1995 16 285 298 7566338
11. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. LF Lue YM Kuo AE Roher L Brachova Y Shen L Sue T Beach JH Kurth RE Rydel J Rogers, Am J Pathol 1999 155 853 862 10487842
12. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. CA McLean RA Cherny FW Fraser SJ Fuller MJ Smith K Beyreuther AI Bush CL Masters, Ann Neurol 1999 46 860 866 10589538
13. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. TC Saido N Iwata, Neurosci Res 2006 54 235 253 16457902
14. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppresion leads to biochemical and pathological deposition. N Iwata S Tsubuki Y Takaki K Watanabe M Sekiguchi E Hosoki M Kawashima-Morishima H.-J Lee E Hama Y Sekine-Aizawa TC Saido, Nature Med 2000 6 143 150 10655101
15. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. K Vekrellis Z Ye WQ Qiu D Walsh D Hartley V Chesneau MR Rosner DJ Selkoe, j Neurosci 2000 20 1657 1665 10684867
16. Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary. HG Bernstein U Lendeckel A Bukowska S Ansorge T Ernst R Stauch K Trubner J Steiner H Dobrowolny B Bogerts, J Chem Neuroanat 2008 35 216 224 18226493
17. Involvement of neutral endopeptidase in neoplastic progression. M Sumitomo R Shen DM Nanus, Biochim Biophys Acta 2005 1751 52 59 16054017
18. Insulysin: an allosteric enzyme as target for Alzheimer's disease. E-S Song L Hersh, J Mol Neurosci 2005 25 201 206 15800373
19. Substrate activation of insulin-degrading enzyme (insulysin) a potential target for drug development. E-S Song M Juliano L Juliano L Hersh, J Biol Chem 2003 278 49789 49794 14527953
20. Acyl peptide hydrolase, a serine proteinase isolated from conditionewd medium of neuroblastoma cells, degrades the amyloid-β peptide. R Yamin S Bagch R Hilderbrant A Scaloni R Widom CR Abraham, J Neurochem 2007 100 458 467 17241160
21. Presence of oxidized protein hydrolase in human cell lines, rat tissues, and human/rat plasma. T Fujino T Tada T Hosaka M Beppu K Kikugawa, J Biochem (Tokyo) 2000 127 307 313
22. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase. T Fujino K Watanabe M Beppu K Kikugawa H Yasuda, Biochemica Biophysica Acta 2000 1478 102 112
23. Overexpression of oxidized protein hydrolase protect COS-7 cells from oxidative stress-induced inhibition of cell growth and survival. K Shimizu T Fujino K Ando M Hayakawa H Yasuda K Kikugawa, Biochem Biophys Res Commun 2003 304 766 771 12727222
24. Coordination of oxidized protein hydrolase and the proteosome in the clearance of cytotoxic denatured proteins. K Shimizu Y Kiuchi K Ando M Hayakawa K Kikugawa, Biochem Biophys Res Commun 2004 324 140 146 15464994
25. Distribution and subcellular localization of acylpeptide hydrolase and acylase I along the Hog gastro-intestinal tract. T Giardina A Biagini D Massey-Harroche A Puigserver, Biochimie 1999 81 1049 1055 10575361
26. Human Acylpeptide Hydrolase studies on its thiol groups and mechanism of action. A Scaloni D Barra W Jones J Manning, J Biol Chem 1994 269 15076 15084 8195144
27. Studies on the specificity of acetylaminoacyl-peptide hydrolase. C Sokolik T Chyau Liang F Wold, Protein Science 1994 3 126 131 8142889
28. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. I Klyubin DM Walsh CA Lemere WK Cullen GM Shankar V Betts ET Spooner L Jiang R Anwyl DJ Selkoe MJ Rowan, Nat Med 2005 11 556 561 15834427
29. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. DM Walsh I Klyubin JV Fadeeva MJ Rowan DJ Selkoe, Biochem Soc Trans 2002 30 552 557 12196135
30. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. JA Fein S Sokolow CA Miller HV Vinters F Yang GM Cole KH Gylys, Am J Pathol 2008 172 1683 1692 18467692
31. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. CC Rowe U Ackerman W Browne R Mulligan KL Pike G O'Keefe H Tochon-Danguy G Chan SU Berlangieri G Jones KL Dickinson-Rowe HP Kung W Zhang MP Kung D Skovronsky T Dyrks G Holl S Krause M Friebe L Lehman S Lindemann LM Dinkelborg CL Masters VL Villemagne, Lancet Neurol 2008 7 129 135 18191617
32. Alzheimer disease: mechanistic understanding predicts novel therapies. DJ Selkoe, Ann Intern Med 2004 140 627 638 15096334
33. The plasmin system is induced by and degrades amyloid-beta aggregates. HM Tucker M Kihiko JN Caldwell S Wright T Kawarabayashi D Price D Walker S Scheff JP McGillis RE Rydel S Estus, J Neurosci 2000 20 3937 3946 10818128
34. Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme. E Eckman D Reed C Eckman, J Biol Chem 2001 276 24540 24548 11337485
35. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. W Farris SG Schutz JR Cirrito GM Shankar X Sun A George MA Leissring DM Walsh WQ Qiu DM Holtzman DJ Selkoe, Am J Pathol 2007 171 241 251 17591969
36. Abeta-degrading enzymes in Alzheimer's disease. JS Miners S Baig J Palmer LE Palmer PG Kehoe S Love, Brain Pathol 2008 18 240 252 18363935
37. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. ME Blomqvist K Chalmers N Andreasen N Bogdanovic GK Wilcock NJ Cairns L Feuk AJ Brookes S Love K Blennow PG Kehoe JA Prince, Neurobiol Aging 2005 26 795 802 15718037
38. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. DG Cook JB Leverenz PJ McMillan JJ Kulstad S Ericksen RA Roth GD Schellenberg LW Jin KS Kovacina S Craft, Am J Pathol 2003 162 313 319 12507914
39. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. K Yasojima H Akiyama EG McGeer PL McGeer, Neurosci Lett 2001 297 97 100 11121879
40. Characterization of a new qQq-FTICR mass spectrometer for post-translational modification analysis and top-down tandem mass spectrometry of whole proteins. JA Jebanathirajah JL Pittman BA Thomson BA Budnik P Kaur M Rape M Kirschner CE Costello PB O'Connor, J Am Soc Mass Spectrom 2005 16 1985 1999 16271296
41. A new hybrid electrospray Fourier transform mass spectrometer: design and performance characteristics. PB O'Connor JL Pittman BA Thomson BA Budnik JC Cournoyer J Jebanathirajah C Lin S Moyer C Zhao, Rapid Commun Mass Spectrom 2006 20 259 266 16353130
42. Removal of polyethylene glycols from protein samples using titanium dioxide. C Zhao PB O'Connor, Anal Biochem 2007 365 283 285 17462581